ARCHIVES

FDA Softening Its Stance On CME Guidelines; New Version To Be More In Line with ACCME

This article is from The Cancer Letter archive.

Vol. 18 No. 14 | April 3, 1992

Download PDF Visit The Full Archive

Related Articles

Phase III Ramucirumab Trial Fails Primary Endpoint of PFS

October 25, 2013

MGMT Gene Can Determine Disease Aggressiveness

June 24, 2011

In Brief: Wyngaarden Suspends NIH Funds for Pennsylvania Head Injury Center Over Animal Care Problems

July 26, 1985

BRAF Mutation Testing Classifies Indeterminate FNA Samples

March 29, 2013

Government Remains open Under Budget Agreement; New Deadlines Are Oct. 5 & 19

October 5, 1990

RFA Available: Chemoprevention Trials

August 5, 1994